Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter.
A patient, partnership-driven family office didn’t wait for fundamentals to break before walking away, and that timing may matter more than the sale itself.
Washington D.C. – December 4, 2025 – A persistent and increasingly vocal debate continues to plague the halls of Congress, centering on allegations that elected officials are leveraging their unique legislative insights for personal financial gain in the stock market. Reports and investigations consistently highlight a concerning trend: members of Congress,
Allogene Therapeutics beat Q3 2025 earnings estimates with a narrower loss and reaffirmed its cash runway into 2027. The biotech also reported progress on its allogeneic CAR T pipeline.
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares (ADSs) from the Nasdaq Capital Market. The news triggered an immediate and dramatic 62.5% plunge in the company's stock during premarket
Allogene Therapeutics reported a Q2 2025 net loss of $0.23 per share, beating estimates, with revenue at $0. Shares rose 1% post-earnings as investors focused on cost discipline and clinical progress.
